No abstract

Prophylactic vaccination against HPV 16 and 18 has the potential for effective prevention of high-grade precancer (cervical intraepithelial neoplasia [CIN)] 2/3) and ICC caused by these viruses (globally 50 and 70%, respectively) when employed in women prior to starting sexual activity. To provide data for decisions on HPV vaccination in China, we determined HPV type-distribution in ICC and CIN 2/3 from women of different regions within China. A multicenter study was conducted by randomized sampling of paraffin blocks of 664 ICC (630 squamous cell carcinoma [SCC]; 34 adenocarcinoma [ADC]), 569 CIN 2/3 cases from seven regions of China. Histological diagnosis was confirmed in 1,233 cases by consensus review. HPV DNA was detected using the SPF10 LiPA25 version 1 assay. HPV prevalence was 97.6% in SCC, 85.3% in adenocarcinoma, and 98.9% in CIN 2/3. HPV 16 (76.7%) and HPV 18 (7.8%) were the most common, together accounting for 84.5% of SCC, followed by HPV 31 (3.2%), HPV 52 (2.2%), and HPV 58 (2.2%). HPV positivity in SCC did not differ notably by region. However, SCC cases from women

Because the activation of telomerase is a relatively early event in the progression of cervical carcinogenesis , the expression of the human telomerase RNA gene , TERC, has the potential to serve as a biomarker for both the diagnosis and prognosis of cervical neoplasias. In total , 83 research centers participated in the study , and 7786 patients were enrolled. TERC amplification was detected using a dual-color fluorescence in situ hybridization (FISH) probe set, and these results were compared with cytological and histological results , testing for high-risk human papillomavirus (HPV) DNA (n ‫؍‬ 2316 for the HPV DNA test), as well as patient age. TERC amplification was found to be increased in more advanced cases of cervical carcinogenesis. Moreover , a Youden's index value and the area under the receiver operating characteristic (ROC) curve were also calculated for samples with TERC amplification and found to be higher than the same values calculated for both cytology and highrisk HPV analyses of the same samples. With regard to cytological ASCUS and LSIL findings , the combination of HPV ؉ TERC testing showed the potential to provide effective triaging to detect CIN2 ؉ . Therefore, TERC amplification represents a valuable genetic biomarker , which in combination with an evaluation of cytology or HPV testing , can achieve higher sensitivity and specificity in distinguishing high-grade cervi- Cervical cancer is the second most common cancer in women, and in 2005, more than 250,000 deaths worldwide were the result of cervical cancer.1 Because ϳ80% of all cervical cancer cases are diagnosed in developing countries, in China, there are ϳ135,000 new cases and 50,000 deaths each year due to this disease.2 Without improvements in the treatments available, the number of cases of cervical cancer are projected to rise by almost 25% over the next 10 years. Therefore, to decrease the incidence and mortality associated with cervical cancer, effective approaches are needed to facilitate the screening and diagnosis of cervical precancerous lesions, especially high-grade lesions.The use of cervical cytopathologic examinations has reduced the incidence of cervical cancer in many countries, 3,4 however the low sensitivity and high variability of this method has limited its significance. 5 With human papillomavirus (HPV) being the main cause of cervical cancer, detection of HPV DNA has become an important supplement to cytologic evaluations performed during cervical cancer screenings.6,7 However, most women who are infected with HPV eliminate the virus and do not progress to high-grade disorders, thereby decreasing the specificity of HPV DNA tests for the detection of cervical cancer. 8 The infection and integration of HPV into epithelial cells are key steps in the induction of malignant alterations in cervical cancer; however, there are additional genomic events that also occur.9 One of the events associated with cervical cancer is an increase in copy number of the long arm of chromosome 3 (3q).

PZH inhibits the growth of HT-29 cells by inducing cancer cell apoptosis via regulation of the Bcl-2 family and activation of caspase 3, which may, in part, explain its anticancer activity.

Tofacitinib (TFT) is an oral JAK inhibitor which has been approved for the treatment of moderately and severely active rheumatoid arthritis. TFT was found to show concentration-, time-, and NADPH-dependent inhibition of CYP3A4, and irreversibility of the inactivation was also observed. Incubation (40 min, 37 °C) of recombinant CYP3A4 with TFT at 200 μM resulted in >70% loss of CYP3A4 activity. Estimated k inact and K I were 0.037 min–1 and 93.2 μM, respectively. GSH and superoxide dismutase/catalase revealed minor or little protection against the CYP3A4 inactivation. Furthermore, ketoconazole attenuated TFT-mediated CYP3A4 inactivation. Epoxide and α-keto-aldehyde intermediates of TFT were trapped and characterized in microsomal incubations, respectively. The aldehyde intermediate is believed to be the key for the enzyme inactivation. Multiple P450 enzymes, including CYPs2C19, 3A4, 2D6, and 1A2, participated in the metabolism of TFT to the epoxide, while the formation of the aldehyde was mainly catalyzed by CYP3A4. In conclusion, TFT was proven to be a mechanism-based inactivator of CYP3A4.

The treatment effect of maintenance pazopanib in East Asian patients seemed to differ from that in non-Asian patients. In study-specific and pooled analyses, none of the potential factors analyzed could satisfactorily explain the different efficacy results of pazopanib in East Asian patients.

No abstract

No abstract